Claremont Financial Group »

Bristol Myers Squibb shares owned by Claremont Financial Group

Quarter-by-quarter ownership of Bristol Myers Squibb (BMY) shares owned by Claremont Financial Group from 13F filings

Historical chart of Claremont Financial Group investment in Bristol Myers Squibb

Tip: Access up to 7 years of quarterly data

All positions including Bristol Myers Squibb held by Claremont Financial Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bristol Myers Squibb by Claremont Financial Group

Quarter filed Position value Share count Share price at filing
2022-03-31 $116k 1.5k 77.33
2021-12-31 $94k 1.5k 62.35

More positions owned by Claremont Financial Group

Vanguard FTSE Developed Markets ETF Exchange Traded Fund (VEA)
SPDR Gold Shares Exchange Traded Fund (GLD)
iShares Core S&P Mid-Cap Exchange Traded Fund (IJH)
iShares Residential & Multisector RE ETF Exchange Traded Fund (REZ)
Vanguard FTSE Emerging Markets ETF Exchange Traded Fund (VWO)
PIMCO Active Bond ETF Exchange Traded Fund (BOND)
Spdr S&p 500 Etf Exchange Traded Fund (SPY)
Vanguard Growth ETF Exchange Traded Fund (VUG)
SPDR Portfolio S&P 600 Sm Cap ETF Exchange Traded Fund (SPSM)
Honeywell International Common Stock (HON)
Union Pacific Corp Common Stock (UNP)
Pfizer Common Stock (PFE)
Invesco S&P 500 Equal Weight ETF Exchange Traded Fund (RSP)
AbbVie Common Stock (ABBV)
Bristol-Myers Squibb Company Common Stock (BMY)

View all positions for Claremont Financial Group

Top funds holding Bristol Myers Squibb

Vanguard Group
BlackRock
State Street Corporation
Jpmorgan Chase & Co
Charles Schwab Investment Management
Geode Capital Management
Ameriprise Financial
Capital Research and Management Company - Division 3
Morgan Stanley
Northern Trust
PRIMECAP Management Company
Ubs Global Asset Management Americas
Independent Franchise Partners
Goldman Sachs Group
Dimensional Fund Advisors

View all funds holding Bristol Myers Squibb